Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Apr 30, 2023 5:24pm
179 Views
Post# 35421923

RE:RE:RE:72% CR at any point in time.

RE:RE:RE:72% CR at any point in time.
wildbird1 wrote: NotinKansas, you start your post exactly the same way that greaterfoolfred does, by saying something that is misleading.

You pretend that the NR patients collect at the bottom. How do you explain patient 22 , this patient is NR from 90 days up to 360 days, and he is not at the bottom of the Swimmer plot.
And there is absolutely no mention anywhere in any Pressrelease that say that the NR patients are send at the bottom of the Swimmer list.

It's obvious from chart and swimmers plot mirrors chart. 52 patients plus 4 non evaluable patients for a total of 56. Includes 12 undetreated at 90 days. Other time points the 12 under treated were removed. Now if in another trial patients were to be given 100 mg of a drug, but 12 patients were wrongly given 15-59 mg ( or 15-59% of intended dose), why in the hell should they be included in final data?  Only to be used in safety analysis perhaps?  That's what happened with the 12 under treated. It was just a matter of time before removal from data. IMHO 
<< Previous
Bullboard Posts
Next >>